Related Experiment Video

Updated: Sep 25, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K

Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?

Gavitt A Woodard1, Christina Cho2, Lieping Chen2

  • 1Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, Yale University, New Haven, Connecticut.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|April 25, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K

Related Experiment Videos

Last Updated: Sep 25, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

Articles linked to this work by shared authors, journal, and citation graph.

Radiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non-small cell lung cancer.

JTCVS open·2026

Siglec-15 and PD-1 checkpoint blockade in combination with oncolytic Zika virus infection confers protection against immune-resistant gliomas.

Neuro-oncology·2026

Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026

The liver-secreted protein FGL1 restrains a subset of innate-like B cell responses via the receptor TACI.

Immunity·2026

CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma.

Translational lung cancer research·2026

Fluoroquinolone Prophylaxis Uncovers High Prevalence Rates of Fluoroquinolone-Resistant Enterobacterales Colonization in Multiple Myeloma Autologous Transplant Patients: A Prospective Cohort Study.

Cancers·2026

Prognostic Significance of Spread Through Airspaces (STAS) in Stage Ia/bN0 Non-small Cell Lung Cancer - An Evaluation in the JCOG0802/WJOG4607L Clinical Trial Patients.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Clinical Responses to Tarlatamab Among Patients with Pulmonary Carcinoid.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Lung Cancer Patient Advocacy Progress and New Challenges Since 2006.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Cannabis Use and Age-Related Acceleration of Psychosis Onset: A Meta-Analysis.

Biological psychiatry·2026

Prognostic importance of tumour deposits with and without concurrent lymph node metastases in patients with stage III colon cancer.

BJS open·2026

Tracking the Temporal Order of Mitochondrial and Lysosomal Damages with a Single Functional Probe: Lysosomal Damage Precedes Mitochondrial Damage under Hyperthermia.

Analytical chemistry·2026

Predictors of Enrolment in a Transoral Surgical Trial for HPV-Related Oropharyngeal Carcinoma.

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·2026

68Ga-NK224 PET/CT Reveals Intra- and Intertumoral Heterogeneity of PD-L1 in Non-Small Cell Lung Cancer.

Radiology·2026

Effect of BMI on efficacy of androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us